{
  "data": {
    "indicator": {
      "slug": "first-in-class-drug-approvals",
      "name": "First-in-class drug approvals",
      "definition": "Number of approved therapeutic drugs featuring a novel biological mechanism of action.",
      "unit": "count",
      "scale": "1",
      "default_unit": "count",
      "default_scale": "1"
    },
    "scale": "1",
    "unit": "count",
    "region": {
      "code": "CN",
      "name": "China",
      "type": "country"
    },
    "points": [
      {
        "period_start": "2022-01-01",
        "period_label": "2022",
        "value": 21,
        "scale": "1",
        "unit": "count",
        "value_type": "actual",
        "statistic_id": "stat_E3DENM4QEGBXFVT0TMPS0FQQNS",
        "url": "https://statorigin.org/stat/stat_E3DENM4QEGBXFVT0TMPS0FQQNS",
        "source_org": "State Council",
        "source": {
          "org": "State Council of China",
          "org_short_name": "State Council",
          "document_title": "Measures facilitate approval of 48 first-in-class innovative drugs",
          "document_url": "https://english.www.gov.cn/news/202503/20/content_WS67db7e91c6d0868f4e8f0fd6.html",
          "locator": "Measures facilitate approval of 48 first-in-class innovative drugs",
          "published_date": null
        }
      },
      {
        "period_start": "2022-01-01",
        "period_label": "2022",
        "value": 21,
        "scale": "1",
        "unit": "count",
        "value_type": "actual",
        "statistic_id": "stat_V2PVD0MBZF95WVXXN20DWVCP41",
        "url": "https://statorigin.org/stat/stat_V2PVD0MBZF95WVXXN20DWVCP41",
        "source_org": "NMPA",
        "source": {
          "org": "National Medical Products Administration",
          "org_short_name": "NMPA",
          "document_title": "Measures facilitate approval of 48 first-in-class innovative drugs",
          "document_url": "https://english.nmpa.gov.cn/2025-03/21/c_1080286.htm",
          "locator": "Measures facilitate approval of 48 first-in-class innovative drugs",
          "published_date": null
        }
      },
      {
        "period_start": "2023-01-01",
        "period_label": "2023",
        "value": 40,
        "scale": "1",
        "unit": "count",
        "value_type": "actual",
        "statistic_id": "stat_B0F5N0J09FDXKE4QQEMHMA6VZD",
        "url": "https://statorigin.org/stat/stat_B0F5N0J09FDXKE4QQEMHMA6VZD",
        "source_org": "State Council",
        "source": {
          "org": "State Council of China",
          "org_short_name": "State Council",
          "document_title": "Measures facilitate approval of 48 first-in-class innovative drugs",
          "document_url": "https://english.www.gov.cn/news/202503/20/content_WS67db7e91c6d0868f4e8f0fd6.html",
          "locator": "Measures facilitate approval of 48 first-in-class innovative drugs",
          "published_date": null
        }
      },
      {
        "period_start": "2023-01-01",
        "period_label": "2023",
        "value": 40,
        "scale": "1",
        "unit": "count",
        "value_type": "actual",
        "statistic_id": "stat_QQAK8A3S9PYQF02R7JY3ZW0M14",
        "url": "https://statorigin.org/stat/stat_QQAK8A3S9PYQF02R7JY3ZW0M14",
        "source_org": "NMPA",
        "source": {
          "org": "National Medical Products Administration",
          "org_short_name": "NMPA",
          "document_title": "Measures facilitate approval of 48 first-in-class innovative drugs",
          "document_url": "https://english.nmpa.gov.cn/2025-03/21/c_1080286.htm",
          "locator": "Measures facilitate approval of 48 first-in-class innovative drugs",
          "published_date": null
        }
      },
      {
        "period_start": "2024-01-01",
        "period_label": "2024",
        "value": 48,
        "scale": "1",
        "unit": "count",
        "value_type": "actual",
        "statistic_id": "stat_M2CT8W1DFWZP0REVGEVMVVD25V",
        "url": "https://statorigin.org/stat/stat_M2CT8W1DFWZP0REVGEVMVVD25V",
        "source_org": "NMPA",
        "source": {
          "org": "National Medical Products Administration",
          "org_short_name": "NMPA",
          "document_title": "China approves 48 innovative drugs in 2024",
          "document_url": "https://english.nmpa.gov.cn/2025-03/19/c_1079532.htm",
          "locator": "China approves 48 innovative drugs in 2024",
          "published_date": null
        }
      },
      {
        "period_start": "2024-01-01",
        "period_label": "2024",
        "value": 48,
        "scale": "1",
        "unit": "count",
        "value_type": "actual",
        "statistic_id": "stat_7ZQGJBK4NK0Z4W8E5R0X0WMRCK",
        "url": "https://statorigin.org/stat/stat_7ZQGJBK4NK0Z4W8E5R0X0WMRCK",
        "source_org": "State Council",
        "source": {
          "org": "State Council of China",
          "org_short_name": "State Council",
          "document_title": "Measures facilitate approval of 48 first-in-class innovative drugs",
          "document_url": "https://english.www.gov.cn/news/202503/20/content_WS67db7e91c6d0868f4e8f0fd6.html",
          "locator": "Measures facilitate approval of 48 first-in-class innovative drugs",
          "published_date": null
        }
      },
      {
        "period_start": "2024-01-01",
        "period_label": "2024",
        "value": 48,
        "scale": "1",
        "unit": "count",
        "value_type": "actual",
        "statistic_id": "stat_KNZB8QGH5G14C6AH9Y1T332SVW",
        "url": "https://statorigin.org/stat/stat_KNZB8QGH5G14C6AH9Y1T332SVW",
        "source_org": "NMPA",
        "source": {
          "org": "National Medical Products Administration",
          "org_short_name": "NMPA",
          "document_title": "Measures facilitate approval of 48 first-in-class innovative drugs",
          "document_url": "https://english.nmpa.gov.cn/2025-03/21/c_1080286.htm",
          "locator": "Measures facilitate approval of 48 first-in-class innovative drugs",
          "published_date": null
        }
      },
      {
        "period_start": "2025-01-01",
        "period_label": "2025",
        "value": 11,
        "scale": "1",
        "unit": "count",
        "value_type": "actual",
        "statistic_id": "stat_50VMAAXPT5DCRGKNXFMP7VT20B",
        "url": "https://statorigin.org/stat/stat_50VMAAXPT5DCRGKNXFMP7VT20B",
        "source_org": "NHSA",
        "source": {
          "org": "National Healthcare Security Administration",
          "org_short_name": "NHSA",
          "document_title": "国家医疗保障局 医保动态 创新高！去年我国批准创新药76个 对外授权破千亿美元",
          "document_url": "https://www.nhsa.gov.cn/art/2026/1/18/art_14_19392.html",
          "locator": "创新高！去年我国批准创新药76个 对外授权破千亿美元",
          "published_date": null
        }
      },
      {
        "period_start": "2025-01-01",
        "period_label": "2025",
        "value": 11,
        "scale": "1",
        "unit": "count",
        "value_type": "actual",
        "statistic_id": "stat_QN0R5EHZ2V5MCK0PF2WYNJAQFW",
        "url": "https://statorigin.org/stat/stat_QN0R5EHZ2V5MCK0PF2WYNJAQFW",
        "source_org": "MOFCOM",
        "source": {
          "org": "Ministry of Commerce of China",
          "org_short_name": "MOFCOM",
          "document_title": "2025年我国批准创新药76个 对外授权超千亿美元",
          "document_url": "https://tradeinservices.mofcom.gov.cn/article/hyly/zyy/zyyfwbmdt/202601/180991.html",
          "locator": "2025年我国批准创新药76个 对外授权超千亿美元",
          "published_date": null
        }
      }
    ],
    "available_regions": [
      "CN"
    ]
  },
  "meta": {
    "attribution": "Data from StatOrigin (https://statorigin.org), CC BY 4.0. Attribution required.",
    "license": "https://creativecommons.org/licenses/by/4.0/",
    "docs": "https://statorigin.org/docs/api",
    "total": 9
  }
}